Korro Bio Inc. (NASDAQ:KRRO) shares climbed 17% on Monday after the Cambridge, Massachusetts-based biopharmaceutical company announced an oversubscribed $85 million private investment in public equity, or PIPE, financing.
The transaction is being led by new investor Venrock Healthcare Capital Partners and includes commitments from a group of new and existing institutional investors: ADAR1 Capital Management, Affinity Asset Advisors, Balyasny Asset Management, Driehaus Capital Management, Kalehua Capital, Lynx1 Capital Management, Nantahala Capital, and New Enterprise Associates.
Under the terms of the subscription agreement, Korro will issue 4,501,928 shares of common stock at $11.11 per share. The company will also issue pre-funded warrants enabling the purchase of 3,148,836 shares at $11.109 per warrant. Those pre-funded warrants carry an exercise price of $0.001 per share. The financing is expected to close on or about Tuesday, March 10, 2026.
Korro said the net proceeds from the PIPE, when combined with its reported $85.2 million in cash, cash equivalents and marketable securities as of December 31, 2025, will push the company’s cash runway into the second half of 2028.
The company stated the funds will support advancing clinical development milestones for several of its pipeline programs. Specifically, Korro highlighted planned clinical data readouts for KRRO-121, its asset for treating hyperammonemia in patients with urea cycle disorders, and progress in its GalNAc-conjugated oligonucleotide program targeting alpha-1 antitrypsin deficiency - both subject to applicable regulatory filings. Korro also intends to advance its longevity and liver health program focused on activating the AMPKγ1 pathway.
Citigroup is acting as a placement agent for the transaction alongside Cantor, Oppenheimer & Co., and William Blair. Korro noted that the securities are being sold in a private transaction, not a public offering, and have not been registered under the Securities Act of 1933.
Market reaction and context
The announcement spurred a notable uptick in Korro’s stock price on the day of the filing. The company framed the financing as a means to fund upcoming clinical milestones and strategic research priorities through mid-2028, contingent on the planned regulatory steps for certain programs.
What remains to be finalized
- The PIPE is expected to close on or about March 10, 2026, subject to customary closing conditions.
- Certain development plans cited are contingent on regulatory filings where noted.